Business Overview: Janel Corporation (OTC: JANL)

---

Executive Summary

Janel Corporation is a small-cap Nevada holding company that owns and operates a collection of mostly unrelated niche businesses across three reportable segments: Logistics, Life Sciences, and Manufacturing. Headquartered in Lake Success, New York, Janel generated roughly $207 million in consolidated revenue in fiscal 2025 (ended September 30, 2025) with net income of about $5 million, against a market capitalization of only around $60 million — a classic micro-cap "conglomerate of small moats" rather than a single-business company with one dominant competitive position. The company has been acquisitive, closing five acquisitions across its segments between February 2024 and September 2025, including freight forwarders Airschott and Interlog USA and the Australian neuroscience biotech Biosensis. Janel also holds a roughly 46.6% equity stake in Rubicon Technology, Inc., a separately-listed sapphire/electronics materials company, giving it an unusual side exposure to a publicly traded minority investment.

---

1. Core Business Model & How They Work

Janel is best understood as a capital allocator that buys and runs small, cash-generative operating businesses rather than as an operator of one integrated business. Each segment has its own customers, competitors, and economics, and corporate management's job is primarily acquisition sourcing, capital allocation, and oversight.

          JANEL CORPORATION (Holding Co.)
                      |
   ---------------------------------------------
   |                  |                         |
LOGISTICS        LIFE SCIENCES              MANUFACTURING
(freight          (antibodies,                (Indco, Inc. —
 forwarding,       reagents, OEM               industrial mixing
 customs           life-science                equipment)
 brokerage,        products)
 trucking)
   |                  |                         |
 Spread/fee      Direct + distributor      Direct + catalog
 income on       sales of ~5,000           sales of standard
 brokered        research/diagnostic       and custom mixers
 freight         products

Each segment earns money differently: Logistics earns the spread between what it pays carriers/providers and what it bills customers (plus flat fees and accessorials like fuel and wait-time charges); Life Sciences sells physical lab products (antibodies, reagents, custom OEM goods) directly and through distributors with fast (typically two-day) order turnaround; and Manufacturing sells industrial mixing equipment built to standard or custom specifications through a company website and a quarterly print catalog.

---

2. Business Segments

FY2025 Segment Mix (illustrative — Logistics is the largest by revenue)
┌─────────────────────────────────────────────┐
│ Logistics        ████████████████████  largest
│ Life Sciences     ██████                 smaller
│ Manufacturing     ████                   smallest
└─────────────────────────────────────────────┘

Logistics. A non-asset-based freight forwarder and customs broker handling air, ocean, and land freight, warehousing, distribution, and trucking. In fiscal 2025 the segment's revenue mix ran roughly 39% trucking, 27% ocean freight, 16% air freight, and 18% customs brokerage and other, across 28 full-service U.S. locations plus independent agents internationally, handling about 148,000 shipments. Customer concentration is very low (largest customer ~3% of revenue; top ten ~17%), which cuts both ways: it limits single-customer risk but also reflects a business with little pricing leverage over any one account. Recent bolt-on acquisitions — Airschott, Interlog USA, and an August 2025 customs-broker asset purchase — are classic consolidation-of-a-fragmented-industry plays.

Life Sciences. Manufactures and distributes antibodies, research and diagnostic reagents, and custom lab services, with a catalog of nearly 5,000 products, serving academic, non-profit, and commercial biomedical research customers. It also does original equipment manufacturing (OEM) for other life-science companies, some of which re-label Janel's products under their own brand. Its main facility is an owned 40-acre site in Davis, California, supplemented by sites in the U.S. and Australia. The February 2024 purchase of ViraQuest and the June 2025 purchase of 80% of Biosensis Pty Ltd (an Australian neuroscience/brain-disease drug-development biotech) extended this segment beyond pure reagent sales toward early-stage biotech R&D exposure.

Manufacturing (Indco, Inc.). Designs, makes, and distributes industrial mixing equipment, both standard models and custom-engineered solutions, for industries including chemicals, inks, paints, plastics, food, and pharmaceuticals. About 84% of fiscal 2025 segment revenue came from Indco's own manufactured products, with the remainder from distributing third-party products; it operates from one owned facility in New Albany, Indiana and shipped roughly 3,600 orders in fiscal 2025.

---

3. Product Portfolio

---

4. Competitive Landscape

• Logistics: Highly fragmented, low barriers to entry, ranging from small "mom-and-pop" forwarders to multinational logistics firms with hundreds of offices (e.g., the scale of players like Expeditors International or C.H. Robinson). Many shippers deliberately use multiple providers, which caps pricing power for any single forwarder, Janel included.
• Life Sciences: Many suppliers compete in protein-related research and diagnostic reagents, from small specialty start-ups to large multinational life-science suppliers (the segment competes in the shadow of giants like Thermo Fisher Scientific and Bio-Techne); customers choose primarily on quality, reputation, and price rather than brand loyalty.
• Manufacturing: Also fragmented with low barriers to entry; Indco competes on price, lead time, service quality, and reach (website and print catalog) against other small industrial mixer makers rather than a dominant global leader.

                 High fragmentation
                        |
   Logistics  ●         |
   Mfg (Indco) ●        |
                        |
Low differentiation ----+---- High differentiation
                        |
                        |      ● Life Sciences (reagent IP/catalog breadth)
                 Low fragmentation

---

5. Strategic Strengths & Risks

Strengths:

• Acquisition-driven diversification across three unrelated end markets reduces exposure to any single industry's downturn.
• Low customer concentration in Logistics limits single-account risk.
• Niche catalog breadth in Life Sciences (~5,000 SKUs) creates switching friction for researchers who standardize protocols around specific reagents.
• Optionality from the Rubicon Technology stake (~46.6% ownership) gives minority-interest upside unrelated to the core operating businesses.

Risks:

• No segment has a structural moat — Logistics and Manufacturing are explicitly described as fragmented, low-barrier-to-entry markets; competitive advantage is thin and must be actively defended through service and price.
• Integration risk from rapid, serial acquisitions (five deals in roughly 18 months), several with deferred minority buyouts (Airschott, Biosensis, Interlog USA) that create future cash obligations and earn-out complexity.
• Micro-cap scale and OTC listing (market cap roughly $60 million against ~$207 million of revenue) mean limited trading liquidity and less analyst/investor scrutiny than exchange-listed peers.
• Biosensis and other early-stage biotech exposure introduces binary R&D risk atypical of Janel's otherwise steady logistics/industrial businesses.

---

6. Financial Overview

---

Summary Conclusion

Janel Corporation is not a single business with a durable competitive moat; it is a diversified holding company whose value depends on management's ability to keep buying and integrating small, cash-generative businesses in fragmented industries at reasonable prices. Its Logistics and Manufacturing segments compete in genuinely low-barrier markets where differentiation is thin, while its Life Sciences segment has the most defensible position thanks to catalog breadth and researcher switching costs, now supplemented by early-stage biotech optionality through Biosensis. The biggest forward risk is execution and integration risk from its rapid acquisition pace, layered on top of the ordinary cyclicality of global freight volumes — making Janel's story one of capital-allocation skill rather than any single structural barrier to competition.